RadNet (RDNT) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $459.7 million, up 13.9% year-over-year, and record Adjusted EBITDA of $72.3 million, up 19.7%, driven by strong demand, advanced imaging, and digital health growth.

• Digital Health segment revenue rose 36.4% to $15.8 million, with AI revenue up 136.6% to $5.6 million, fueled by EBCD AI-powered mammography and increased investments.

• Net loss of $3.0 million for Q2 2024, compared to net income of $8.4 million in Q2 2023, primarily due to higher interest expense, debt extinguishment costs, and non-recurring items.

• Major expansion into Houston, Texas, with two acquisitions totaling 13 imaging centers, and expanded joint ventures, now with 37.4% of centers in health system partnerships.

• Raised 2024 guidance for revenue, Adjusted EBITDA, and free cash flow based on strong performance and continued investment in de novo centers and AI initiatives.

Financial highlights

• Q2 2024 revenue: $459.7 million (+13.9% YoY); Adjusted EBITDA: $72.3 million (+19.7% YoY); Adjusted EBITDA margin: 15.7% (+76 bps YoY).

• Imaging Center segment: $443.9 million revenue (+13.2% YoY), $69.1 million Adjusted EBITDA (+16.9% YoY).

• Digital Health segment: $15.8 million revenue (+36.4% YoY), $3.3 million Adjusted EBITDA (+135.2% YoY).

• Net loss per share: -$0.04 (vs. $0.12 EPS in Q2 2023), impacted by non-cash and one-time items.

• Cash and cash equivalents at June 30, 2024: $741.7 million, up from $342.6 million at year-end 2023.

Outlook and guidance

• 2024 revenue guidance raised to $1.685B–$1.735B; Adjusted EBITDA to $257M–$267M; free cash flow to $72M–$80M.

• Capital expenditures for Imaging Center segment increased to $135M–$145M.

• Digital Health segment guidance unchanged: $60M–$70M revenue, $13M–$15M Adjusted EBITDA; segment expected to generate net losses as investments continue.

• 2025 Medicare reimbursement cut of $6M–$8M expected, but offset by commercial and capitated payer increases.

• Sufficient liquidity and borrowing capacity to fund operations and future acquisitions over the next twelve months.